Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P. Morgan Week 2022”

On December 20, 2021 Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) ("Diffusion" or the "Company"), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, reported that the Company will present at H.C. Wainwright BioConnect and participate in Biotech Showcase and BIO Partnering at JPM (Press release, Diffusion Pharmaceuticals, DEC 20, 2021, View Source [SID1234597951]). All three events are scheduled alongside the J.P. Morgan 40th Annual Healthcare Conference 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

Event: Biotech Showcase
Date: January 10-12, 2022
Registration: https://informaconnect.com/biotech-showcase/registration-options/

Event: H.C. Wainwright BioConnect
Date: January 10-13, 2022
Registration: View Source

Event: BIO Partnering at JPM
Date: January 10-14, 2022
Registration: View Source
During the conference events, members of the Diffusion management team will participate in virtual one-on-one meetings with registered investors and pharmaceutical companies.

Registered attendees in the H.C. Wainwright BioConnect conference will be able to view a prerecorded, virtual presentation by Diffusion CEO Robert Cobuzzi, Jr., Ph.D. highlighting Diffusion’s business and recent corporate achievements, including the recently announced dosing of the first participants and patients in its last two Oxygenation Trials, the Altitude and ILD-DLCO Trials, with its lead product candidate, trans sodium crocetinate, or TSC. Dr. Cobuzzi also will describe certain aspects of the Company’s rationale for its plans to design and execute a clinical program to support the use of intravenously administered TSC as an adjunctive treatment for hypoxic solid tumors.